We assessed the success rate of vancomycin catheter lock therapy (VLT) in combination with systemic antimicrobials in patients with staphylococcal catheter‐related bloodstream infection (C‐RBSI). Over a 6‐year period, we retrospectively collected clinical and microbiological data from patients with long‐term central venous catheters and staphylococcal C‐RBSI who were treated with systemic antimicrobials and VLT. We then assessed the success rate of VLT based on two criteria: 1) catheter retention time> 3 months and 2) catheter in place until end of use. We found 217 staphylococcal C‐RBSI episodes, 115 (53.0%) of which were managed with conservative therapy. Of these, 76 (66.1%) were treated with VLT (85.5% coagulase‐negative staphylococci and 14.5% Staphylococcus aureus ). The success rate of VLT was 42.1% with criterion 1 and 71.1% with criterion 2. We did not find statistically significant differences between success and failure in the majority of the clinical data recorded. We only found differences for crude mortality in criterion 1 and for parenteral nutrition in criterion 2. The success of catheter retention using VLT was moderate, reaching slightly more than 70% when the catheter was kept in place until the end of use.

中文翻译：

---

万古霉素锁定疗法能否延长受感染长期导管的保留时间？

我们评估了万古霉素导管锁定疗法（VLT）结合全身性抗生素治疗葡萄球菌导管相关性血流感染（C-RBSI）的成功率。在6年的时间里，我们回顾性收集了长期接受中心静脉导管和葡萄球菌C-RBSI的患者的临床和微生物学数据，这些患者接受了全身性抗生素和VLT治疗。然后，我们基于两个标准评估了VLT的成功率：1）导管保留时间> 3个月，以及2）导管就位直至使用结束。我们发现217例葡萄球菌C-RBSI发作，其中115例（53.0％）采用保守疗法治疗。其中76例（66.1％）接受了VLT治疗（85.5％凝固酶阴性葡萄球菌和14.5％的金黄色葡萄球菌））。在标准1下，VLT的成功率为42.1％，在标准2下为71.1％。我们在记录的大多数临床数据中，未发现成功与失败之间的统计学差异。我们仅发现标准1中的粗死亡率和标准2中的肠胃外营养差异。使用VLT进行导管保留的成功率是中等的，当将导管放置到位直至使用结束时，其成功保留率略高于70％。